Top

Published in:

Open Access 01-12-2014 | Research article

Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered

Authors: Kazuhiro Tabata, Tomonori Tanaka, Tomayoshi Hayashi, Takashi Hori, Sayuri Nunomura, Suguru Yonezawa, Junya Fukuoka

Published in: BMC Clinical Pathology | Issue 1/2014

Abstract

Background

Ki-67 expression is a well-established prognostic marker in various cancers. However, Ki-67 expression is also known as being heterogeneous. We investigated the prognostic significance of Ki-67 from the view of staining heterogeneity by the technique of Spiral Array.

Methods

100 cases of resected lung cancer from Toyama university hospital archive were collected. Spiral Array blocks were generated out of 100 cases using 100 μm thick paraffin sections. Four μm thick sections of the Array block were stained for Ki-67. Staining results in each reel were scored for areas with lowest (LS), highest (HS), and average (AS) expression, exclusively in the cancer cells. Heterogeneity score (HeS) was designed as the difference between HS and LS. The scores were divided into four grades (0–3). Clinical information was collected, and the prognostic significance of Ki-67 was analyzed.

Results

Pathological stage was available for 91 patients (43 stage IA, 22 stage IB, 2 stage IIA, 9 stage IIB, 13 stage IIIA, 1 stage IIIB, and 1 stage IV). The HS of Ki-67 score in non-small cell lung cancer was 3 in 17 cases, 2 in 27 cases, 1 in 28 cases, 0 in 21 cases, and 4 reels were lost. 78 cases had clinical follow up. 74 cases had all the information available and were analyzed for correlation between Ki-67 expression and survival. Cases with score 2 and 3 of HS and HeS showed significant poorer prognosis (both P < 0.001), whereas LS or AS did not show significance. The results were identical when analyzing adenocarcinoma and squamous cell carcinoma, separately. Cox multivariate analysis of Ki-67 showed that HS was an independent risk factor affecting overall survival.

Conclusions

Ki-67 is a strong prognostic marker for non-small cell lung cancer when the degree of highest staining frequency or heterogeneity is considered.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.CrossRefPubMed

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J immunol. 1984, 133 (4): 1710-1715.PubMed

Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P: Proliferation index as a prognostic marker in breast cancer. Cancer. 1993, 71 (12): 3926-3931. 10.1002/1097-0142(19930615)71:12<3926::AID-CNCR2820711221>3.0.CO;2-2.CrossRefPubMed

Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M: Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 2010, 28 (2): 145-151. 10.1016/j.urolonc.2008.08.001.CrossRefPubMed

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Tetu B, Meyer F, Fradet Y: Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors. Hum Pathol. 1999, 30 (11): 1350-1355. 10.1016/S0046-8177(99)90067-9.CrossRefPubMed

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O: Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum Pathol. 2013, 44 (1): 39-46. 10.1016/j.humpath.2012.05.007.CrossRefPubMed

Jamali M, Chetty R: Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008, 19 (4): 282-288. 10.1007/s12022-008-9044-0.CrossRefPubMed

Macdonald C, Michael A, Colston K, Mansi J: Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma. European J Cancer. 2004, 40 (3): 461-466. 10.1016/j.ejca.2003.10.019.CrossRef

Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O, Colnot N, Paradis V, Belghiti J, Bedossa P, Ruszniewski P: Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol: an official Jof the United States and Canadian Academy of Pathology, Inc. 2009, 22 (2): 273-281. 10.1038/modpathol.2008.177.CrossRef

10.

Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H, Hayabuchi N, Hirohashi S: Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003, 27 (7): 937-951. 10.1097/00000478-200307000-00009.CrossRefPubMed

11.

Fukuoka J, Hofer MD, Hori T, Tanaka T, Ishizawa S, Nomoto K, Saito M, Uemura T, Chirieac LR: Spiral array: a new high-throughput technology covers tissue heterogeneity. Arch Pathol Lab Med. 2012, 136 (11): 1377-1384. 10.5858/arpa.2011-0393-OA.CrossRefPubMed

12.

Patohology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Edited by: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. 2004, Lyon: IARC Press

13.

Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H, Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H: Application of a new technique, spiral tissue microarrays constructed using needle biopsy specimens, to prostate cancer research. Int J Oncol. 2014, 44 (1): 195-202.PubMed

14.

Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, Fujisawa T, Ohwada H: Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer. Ann Thorac Surg. 2003, 75 (6): 1727-1732. 10.1016/S0003-4975(03)00119-X. discussion 1732–1723CrossRefPubMed

15.

Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, Ogura S, Shimizu M, Katoh H, Kawakami Y: Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000, 6 (10): 4073-4081.PubMed

16.

Inoue M, Takakuwa T, Minami M, Shiono H, Utsumi T, Kadota Y, Nasu T, Aozasa K, Okumura M: Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung. J Thorac Cardiovas Surg. 2008, 135 (4): 830-836. 10.1016/j.jtcvs.2007.10.034.CrossRef

17.

Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T: EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2008, 26 (34): 5589-5595. 10.1200/JCO.2008.16.7254.CrossRef

18.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012, 30 (8): 863-870. 10.1200/JCO.2011.35.6345.CrossRefPubMedPubMedCentral

19.

Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67 in Breast Cancer Working G: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Nat Cancer Inst. 2011, 103 (22): 1656-1664. 10.1093/jnci/djr393.CrossRefPubMedPubMedCentral

20.

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S: The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010, 39 (6): 707-712. 10.1097/MPA.0b013e3181ec124e.CrossRefPubMed

21.

Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, Schmechel SC, Lange H: Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest. 2012, 92 (9): 1342-1357. 10.1038/labinvest.2012.91.CrossRefPubMed

22.

Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007, 356 (8): 800-808. 10.1056/NEJMoa065411.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6890/14/23/prepub

Title: Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered
Authors: Kazuhiro Tabata
Tomonori Tanaka
Tomayoshi Hayashi
Takashi Hori
Sayuri Nunomura
Suguru Yonezawa
Junya Fukuoka
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Clinical Pathology / Issue 1/2014
Electronic ISSN: 1472-6890
DOI: https://doi.org/10.1186/1472-6890-14-23

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

DKK-1 in prostate cancer diagnosis and follow up

Implant based differences in adverse local tissue reaction in failed total hip arthroplasties: a morphological and immunohistochemical study

Clinico-pathological features of tuberculosis due to Mycobacterium tuberculosis Uganda genotype in patients with tuberculous lymphadenitis: a cross sectional study

Evaluation of a solid matrix for collection and ambient storage of RNA from whole blood

A case of EDTA-dependent pseudothrombocytopenia: simple recognition of an underdiagnosed and misleading phenomenon

Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials